Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6113452 | 0.73 | — | — | |
| SCHEMBL3273225 | 0.73 | — | — | |
| SCHEMBL14790645 | 0.70 | USP2 (0.35) | — | |
| SCHEMBL2166932 | 0.69 | — | — | |
| SCHEMBL15352693 | 0.69 | — | — | |
| SCHEMBL2906410 | 0.69 | — | — | |
| SCHEMBL19396334 | 0.69 | — | — | |
| SCHEMBL2167596 | 0.69 | — | — | |
| SCHEMBL2166750 | 0.68 | — | — | |
| SCHEMBL3794679 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236445-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF ALZHEIMER'S DISEASE IN PATIENTS HAVING LOST RESPONSIVENESS TO ACETYLCHOLINESTERASE INHIBITOR THERAPY | PHARNEXT (FR) | 2021-08-05 | — | — | US | disclosed |
| EP-3443955-B1 | PHARMACEUTICAL COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE | PHARNEXT (FR) | 2021-06-16 | — | — | EP | disclosed |
| US-20210069135-A1 | THERAPEUTIC APPROACHES FOR TREATING EPILEPSY AND RELATED DISORDERS THROUGH REDUCTION OF EPILEPTOGENESIS | PHARNEXT (FR) | 2021-03-11 | — | — | US | disclosed |
| US-10905672-B2 | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders | PHARNEXT (FR) | 2021-02-02 | — | — | US | disclosed |
| EP-3746062-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF ALZHEIMER'S DISEASE IN PATIENTS HAVING LOST RESPONSIVENESS TO ACETYLCHOLINESTERASE INHIBITOR THERAPY | Pharnext (FR) | 2020-12-09 | — | — | EP | disclosed |
| EP-3348261-B1 | NEW COMPOSITIONS COMPRISING BACLOFEN, ACAMPROSATE AND RILUZOLE | PHARNEXT (FR) | 2020-10-21 | — | — | EP | disclosed |
| US-10799499-B2 | Combinatorial therapies of neurological disorders | PHARNEXT (FR) | 2020-10-13 | — | — | US | disclosed |
| US-10736876-B2 | Idalopirdine-based combinatorial therapies of Alzheimer's disease | PHARNEXT (FR) | 2020-08-11 | — | — | US | disclosed |
| US-10682342-B2 | Compositions for treating amyotrophic lateral sclerosis | PHARNEXT (FR) | 2020-06-16 | — | — | US | disclosed |
| US-20200129479-A1 | IDALOPIRDINE-BASED COMBINATORIAL THERAPIES OF ALZHEIMER'S DISEASE | PHARNEXT (FR) | 2020-04-30 | — | — | US | disclosed |
| WO-2009052191-A1 | INTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099253-A1 | Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use | XENOPORT, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090082440-A1 | SIMPLE PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2009033069-A1 | SIMPLE PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009033061-A1 | MASKED CARBOXYLATE NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009033061-A1 | MASKED CARBOXYLATE NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009033061-A1 | MASKED CARBOXYLATE NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090069419-A1 | MASKED CARBOXYLATE NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069419-A1 | MASKED CARBOXYLATE NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069419-A1 | MASKED CARBOXYLATE NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069419-A1 | MASKED CARBOXYLATE NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, AASDHPPT, ACMSD | TDP1 1702/4885 |
| US-10905672-B2 | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders | CPT1B, APOB, GABRB3 | TDP1 389/4885 |
| US-20090082440-A1 | SIMPLE PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, SLC19A1, SLC25A21 | TDP1 2069/4885 |
| US-20090099253-A1 | Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use | SI, AASDHPPT, PSAP | TDP1 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.